Armata Pharmaceuticals Announces Material Agreement and Officer Changes
Ticker: ARMP · Form: 8-K · Filed: Nov 15, 2024 · CIK: 921114
| Field | Detail |
|---|---|
| Company | Armata Pharmaceuticals, INC. (ARMP) |
| Form Type | 8-K |
| Filed Date | Nov 15, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, officer-changes, board-changes
TL;DR
Armata Pharma inked a big deal & shuffled execs on Nov 12. Details pending.
AI Summary
Armata Pharmaceuticals, Inc. announced on November 12, 2024, the entry into a material definitive agreement and changes in its board of directors and officer appointments. The company also filed financial statements and exhibits related to these events. Specific details regarding the agreement and the compensatory arrangements for officers were not immediately disclosed in this filing.
Why It Matters
This filing indicates significant corporate actions, including a new material agreement and potential changes in leadership, which could impact the company's strategic direction and financial performance.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and changes in officers, which can introduce uncertainty and potential shifts in company strategy.
Key Players & Entities
- Armata Pharmaceuticals, Inc. (company) — Registrant
- November 12, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Armata Pharmaceuticals?
The filing states that Armata Pharmaceuticals, Inc. entered into a material definitive agreement on November 12, 2024, but the specific terms and details of this agreement are not provided in this initial 8-K filing.
What specific changes occurred regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, as well as compensatory arrangements for certain officers, but does not name the individuals involved or the specifics of the arrangements.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on November 12, 2024.
What other items are being reported in this 8-K filing besides the material agreement and officer changes?
In addition to the material definitive agreement and changes in directors/officers, the filing also reports on financial statements and exhibits.
What is Armata Pharmaceuticals, Inc.'s state of incorporation?
Armata Pharmaceuticals, Inc. is incorporated in Washington (WA).
Filing Stats: 924 words · 4 min read · ~3 pages · Grade level 12.9 · Accepted 2024-11-15 16:05:32
Filing Documents
- tm2428608d1_8k.htm (8-K) — 29KB
- tm2428608d1_ex10-1.htm (EX-10.1) — 31KB
- tm2428608d1_ex10-2.htm (EX-10.2) — 31KB
- 0001104659-24-119701.txt ( ) — 276KB
- armp-20241112.xsd (EX-101.SCH) — 3KB
- armp-20241112_lab.xml (EX-101.LAB) — 33KB
- armp-20241112_pre.xml (EX-101.PRE) — 22KB
- tm2428608d1_8k_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On November 12, 2024, the Company entered into amendments to (i) that certain credit and security agreement (as amended, the "Credit Agreement"), dated as of July 10, 2023, by and among the Company, as borrower, Innoviva Strategic Opportunities LLC ("Innoviva"), as lender, and certain domestic subsidiaries of the Company, as guarantors (the "Second Amendment to Credit Agreement") and (ii) that certain convertible credit and security agreement (as amended, the "Convertible Credit Agreement"), dated as of January 10, 2023, by and among the Company, as borrower, Innoviva, as lender, and certain domestic subsidiaries of the Company, as guarantors (the "Third Amendment to Convertible Credit Agreement" and together with the Second Amendment to Credit Agreement, the "Amendments"). Pursuant to the Amendments, the parties agreed to extend the maturity dates of the Credit Agreement and Convertible Credit Agreement to January 10, 2026. The foregoing descriptions of the Second Amendment to Credit Agreement and the Third Amendment to Convertible Credit Agreement are qualified in their entirety by the full text of such documents, which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, and are incorporated herein by reference. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On November 13, 2024 (the "Termination Date"), the Company terminated the employment of Mina Pastagia, M.D. ("Dr. Pastagia"), Chief Medical Officer of the Company, effective as of the close of business on the Termination Date. The Company is grateful to Dr. Pastagia and wishes her well in her future endeavors. Pursuant to the terms of her employment agreement, in consideration for Dr. Pastagia's general release of claims in favor of the Company and its affiliates, Dr. Pastagia is eligible to receive continued payment of her base sa
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d)Exhibits 10.1 Second Amendment to Credit and Security Agreement, dated as of November 12, 2024, by and among the Issuer, Innoviva Sub and the other parties thereto. 10.2 Third Amendment to Secured Convertible Credit and Security Agreement, dated as of November 12, 2024, by and among the Issuer, Innoviva Sub and the other parties thereto. 104 Cover Page Interactive Data File (embedded within XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 15, 2024 Armata Pharmaceuticals, Inc. By: /s/ David House Name: David House Title: Senior Vice President, Finance and Principal Financial Officer